United States Patent 4,378,971 Method and apparatus for quantitatively determining the level of hemoglobin in a biological sample. 1983 April 5, accessioned 2010 November 3 as full PDF at http://www.freepatentsonline.com/4378971.pdf
guideline.gov
Effectiveness of Colorectal Cancer Screening Tests: Colorectal cancer screening clinical practice guideline. National Guideline Clearinghouse (NGC), a U.S. government-provided resource for evidence-based clinical practice guidelines, at https://www.guideline.gov/summary/summary.aspx?doc_id=14345
nih.gov
ncbi.nlm.nih.gov
Harewood GC, Ahlquist DA (2000). "Fecal occult blood testing for iron deficiency: a reappraisal". Dig Dis 18 (2): 75–82. doi:10.1159/000016968. PMID 11060470.
Bardhan PK, Beltinger J, Beltinger RW, Hossain A, Mahalanabis D, Gyr K (January 2000). "Screening of patients with acute infectious diarrhoea: evaluation of clinical features, faecal microscopy, and faecal occult blood testing". Scand. J. Gastroenterol. 35 (1): 54–60. doi:10.1080/003655200750024533. PMID 10672835.
Young GP, Cole SR (March 2009). "Which fecal occult blood test is best to screen for colorectal cancer?". Nat Clin Pract Gastroenterol Hepatol 6 (3): 140–1. doi:10.1038/ncpgasthep1358. PMID 19174764.
Grazzini G, Visioli CB, Zorzi M et al (January 2009). "Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening?". Br. J. Cancer 100 (2): 259–65. doi:10.1038/sj.bjc.6604864. PMC 2634712. PMID 19142185.
Berchi C, Bouvier V, Réaud JM, Launoy G (March 2004). "Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France". Health Econ 13 (3): 227–38. doi:10.1002/hec.819. PMID 14981648.
Kuriyama M, Kato J, Takemoto K, Hiraoka S, Okada H, Yamamoto K (March 2010). "Prediction of flare-ups of ulcerative colitis using quantitative immunochemical fecal occult blood test". World J. Gastroenterol. 16 (9): 1110–4. doi:10.3748/wjg.v16.i9.1110. PMC 2835788. PMID 20205282.
Jin YM, Li BJ, Qu B, Du YJ. "BRAF, K-ras and BAT26 mutations in colorectal polyps and stool"]. World J. Gastroenterol. 12 (32): 5148–52. PMID 16937524
Cravo M, Lage P, Albuquerque C et al (July 1999). "BAT-26 identifies sporadic colorectal cancers with mutator phenotype: a correlative study with clinico-pathological features and mutations in mismatch repair genes". J. Pathol. 188 (3): 252–7. doi:10.1002/(SICI)1096-9896(199907)188:3<252::AID-PATH354>3.0.CO;2-3. PMID 10419591.
van Rossum LG, van Rijn AF, van Oijen MG et al (August 2009). "False negative fecal occult blood tests due to delayed sample return in colorectal cancer screening". Int. J. Cancer 125 (4): 746–50. doi:10.1002/ijc.24458. PMID 19408302.
Harewood GC, McConnell JP, Harrington JJ, Mahoney DW, Ahlquist DA (January 2002). "Detection of occult upper gastrointestinal tract bleeding: performance differences in fecal occult blood tests". Mayo Clin. Proc. 77 (1): 23–8. doi:10.4065/77.1.23. PMID 11794453.
Whitlock EP, Lin J, Liles E, Beil T, Fu R, O'Connor E, Thompson RN, Cardenas T (2008). "Screening for Colorectal Cancer: An Updated Systematic Review". Agency for Healthcare Research and Quality (US); 2008 Oct. Report No.: 08-05-05124-EF-1.. PMID 20722162
Hawkins NJ, Ward RL (September 2001). "Sporadic colorectal cancers with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas". J. Natl. Cancer Inst. 93 (17): 1307–13. doi:10.1093/jnci/93.17.1307. PMID 11535705.
Hamilton SR (September 2001). "Origin of colorectal cancers in hyperplastic polyps and serrated adenomas: another truism bites the dust". J. Natl. Cancer Inst. 93 (17): 1282–3. doi:10.1093/jnci/93.17.1282. PMID 11535695.
Lüchtenborg M, Weijenberg MP, Wark PA et al (2005). "Mutations in APC, CTNNB1 and K-ras genes and expression of hMLH1 in sporadic colorectal carcinomas from the Netherlands Cohort Study". BMC Cancer 5: 160. doi:10.1186/1471-2407-5-160. PMC 1334229. PMID 16356174.
Rockey DC (December 2005). "Occult gastrointestinal bleeding". Gastroenterol. Clin. North Am. 34 (4): 699–718. doi:10.1016/j.gtc.2005.08.010. PMID 16303578.
Walleser S, Griffiths A, Lord SJ, Howard K, Solomon MJ, Gebski V (December 2007). "What is the value of computerized tomographic colonography in patients screening positive for fecal occult blood? A systematic review and economic evaluation". Clin. Gastroenterol. Hepatol. 5 (12): 1439–46; quiz 1368. doi:10.1016/j.cgh.2007.09.003. PMID 18054752.
Levi Z, Gal E, Vilkin A, Chonen Y, Belfer RG, Fraser G, Niv Y. Fecal immunochemical test and small bowel lesions detected on capsule endoscopy: results of a prospective study in patients with obscure occult gastrointestinal bleeding. Eur J Gastroenterol Hepatol. 2011 Nov;23(11):1024-8. PMID 21975696
Rockey DC Gastrointestinal tract evaluation in patients with iron deficiency anemia. Semin Gastrointest Dis. 1999 Apr;10(2):53-64. PMID 10361896
Nakama H, Zhang B, Fattah AS, Zhang X. Colorectal cancer in iron deficiency anemia with a positive result on immunochemical fecal occult blood. Int J Colorectal Dis. 2000 Nov;15(5-6):271-4. PMID 11151429
Wang GQ. [Screening for upper G-I tract cancer by gastroscopy in a 2,000 suspected population]. [Article in Chinese] Zhonghua Zhong Liu Za Zhi. 1989 May;11(3):201-3. PMID 2612334
Qin D, Wang G, Zhang X, Zuo J. Inspection for gastric occult blood at regular intervals is the optimum program for the screening of esophageal-gastric cancer. Ann Ital Chir. 1995 Jan-Feb;66(1):41-4; discussion 45-6. PMID 7668481
web.archive.org
PreGen-Plus™ Fact Sheet. full text accessioned 2010 November 3 at Copia archiviata (PDF), su noaw.com. URL consultato il 3 novembre 2010 (archiviato dall'url originale il 2 gennaio 2011).
Baylin SB,Futscher BW, Gore SD. Understanding DNA Methylation and Epigenetic Gene Silencing in Cancer. Papers from a
symposium held June 4, 2004, in New Orleans, Louisiana. URL consultato in data 7 aprile 2012. Copia archiviata (PDF), su static.cjp.com. URL consultato il 3 novembre 2010 (archiviato dall'url originale il 22 maggio 2011).
